Related Experiment Video

Updated: Jul 12, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Oncostatin M Induces IFITM1 Expression to Inhibit Hepatitis B Virus Replication Via JAK-STAT Signaling

Yuchen Ye1, Ya Fu2, Caorui Lin2

  • 1Department of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China; Clinical Laboratory Diagnostics, The First Clinical College, Fujian Medical University, Fuzhou, China.

Cellular and Molecular Gastroenterology and Hepatology
|October 25, 2023
PubMed
Abstract

Insights

Oncostatin M (OSM) effectively suppresses hepatitis B virus (HBV) replication by remodeling immune responses. This cytokine shows promise as a novel therapeutic for chronic hepatitis B (CHB) infection.

Area of Science:

  • Immunology
  • Virology
  • Hepatology

Background:

  • Limited functional cure rates for chronic hepatitis B (CHB) necessitate novel therapeutic strategies.
  • Current treatments like nucleotide analogues and interferon have restricted efficacy.
  • Developing new therapies to improve functional cure rates in CHB patients is crucial.

Purpose of the Study:

  • To investigate the anti-hepatitis B virus (HBV) potential of interleukin-6 family cytokines.
  • To identify the most potent cytokine and elucidate its mechanism of action against HBV.
  • To evaluate Oncostatin M (OSM) as a therapeutic candidate for CHB.

Main Methods:

  • Screening of interleukin-6 family cytokines using HBV-infected cells.
  • Quantification of Oncostatin M (OSM) levels in CHB patients via ELISA.
  • Mechanism exploration using RNA-sequencing and in vivo studies in HBV-infected mice.

Main Results:

  • Oncostatin M (OSM) demonstrated significant suppression of HBV replication (HBsAg, HBeAg, HBV DNA).
  • Higher OSM levels correlated with lower viral markers in CHB patients.
  • OSM activates the JAK-STAT pathway, inducing antiviral gene expression, including Interferon-induced transmembrane protein 1.

Conclusions:

  • Oncostatin M (OSM) exhibits potent anti-HBV activity by modulating immune responses.
  • OSM shows potential as a therapeutic agent for chronic hepatitis B (CHB).
  • Further development of OSM for CHB treatment is warranted.
Keywords:
Hepatitis B VirusInterferon-Induced Transmembrane Protein 1Interleukin-6 Family CytokinesJAK-STAT SignalingOncostatin M

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF311:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.0K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K